Seeking Alpha
20 Nov 2026, 15:53 UTC · 5h ago
Erasca: 'Buy' On Expanded KRAS Targeting ERAS-4001 And Bristol-Myers Squibb Collaboration Tie-Up
Impact · against what's priced in
The article provides a bullish outlook for Erasca, but the clinical data and collaborations it cites are largely already accounted for by the market's current valuation of the pipeline. While the author suggests safety and patent overhangs have subsided, there is no concrete evidence provided to overturn the market's pricing of the Phase 1 patient death or the litigation with Revolution Medicines.
- ERAS+0.20
Challenges what's priced in
- The price assumes





